Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49ΔCH2) in recurrent and metastatic colorectal cancer patients

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 1, 2005, Pages 16-26

  Xiao, Jim ^a   Horst, Sara ^a   Hinkle, George ^a   Cao, Xianhua ^a   Kocak, Ergun ^a   Fang, Jing ^a   Young, Donn ^a   Khazaeli, M ^b   Agnese, Doreen ^a   Sun, Duxin ^a   Martin Jr , Edward ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

HAMA; HuCC49 CH2 MAb; Humanized CC49 antibody; Pharmacokinetics; Radioimmunoguided surgery (RIGS); Tumor localization

Indexed keywords

IODINE 125; MONOCLONAL ANTIBODY CC49;

ADULT; AGED; AORTA BIFURCATION; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; ISOTOPE LABELING; LAPAROTOMY; MALE; MOLECULAR PROBE; PARTITION COEFFICIENT; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN STRUCTURE, TERTIARY; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RECURRENCE; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 20144389618     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.16     Document Type: Article

References (33)

1. Cook CH, Hinkle GH, Thurston MO, et al. Pharmacokinetics of iodine-125 CC49 monoclonal antibody in patients with colon cancer. Cancer Biother Radiopharm 1996;11:415.
2. Arnold MW, Schneebaum S, Berens A, et al. Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery 1992;112:624.
3. Bertsch DJ, Burak WE, Young DC, et al. Radioimmunoguided surgery system improves survival for patients with recurrent colorectal cancer. Surgery 1995;118:634.
4. Bakalakos EA, Burak WE. The radioimmunoguided surgery (RIGS) system as a diagnostic tool. Surg Oncol Clin N Am 1999;8:129.
5. Colcher D, Minelli MF, Roselli M, et al. Radioimmunolocalization of human carcinoma xenografts with B72.3 second-generation monoclonal antibodies. Cancer Res 1988;48:4597.
6. Colcher D, Milenic DE, Roselli M, et al. In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72. Int J Rad Appl Instrum B 1991;18:395.
7. 125I-radiolabeled monoclonal antibody CC49. Cancer 1996;77:613.
8. Nuti M, Teramoto YA, Mariani-Costantini R, et al. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 1982;29:539.
9. Johnson VG, Schlom J, Paterson AJ, et al. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986;46:850.
10. Szpak CA, Johnston WW, Roggli V, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 1986;122:252.
11. Thor A, Viglione MJ, Ohuchi M, et al. Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. Breast Cancer Res Treat 1988;11:133.
12. Colcher D, Keenan AM, Larson SM, et al. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res 1984;44:5754.
13. Muraro R, Kuroki M, Wunderlich D, et al. Generation and characterization of B72.3 second-generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988;48:4588.
14. Schlom J, Colcher D, Siler K, et al. Tumor targeting with monoclonal antibody B72.3: Experimental and clinical results. Cancer Treat Res 1990;51:313.
15. Cohen AM, Martin EW Jr, Lavery I, et al. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg 1991;126:349.
16. Kashmiri SV, Shu VL, Padlan EA, et al. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 1995;14:461.
17. Nag S, Martinez-Monge R, Martin EW Jr. Radioimmunoguided-intraoperative radiation therapy in colorectal carcinoma: a new technique to precisely define the clinical target volume. Int J Radiat Oncol Biol Phys 1999;44:133.
18. Nieroda CA, Mojzisik C, Sardi A, et al. The impact of radioimmunoguided surgery (RIGS) on surgical decision making in colorectal cancer. Dis Colon Rectum 1989;32:927.
19. Sardi A, Workman M, Mojzisik C, et al. Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system). Arch Surg 1989;124:55.
20. Arnold MW, Young DM, Hitchcock CL, et al. Staging of colorectal cancer: Biology versus morphology. Dis Colon Rectum 1998;41:1482.
21. Arnold MW, Schneebaum S, Martin EW Jr. Radioimmunoguided surgery in the treatment and evaluation of rectal cancer patients. Cancer Control 1996;3:42.
22. Reynolds JC, Del Vecchio S, Sakahara H, et al. Antimurine antibody response to mouse monoclonal antibodies: Clinical findings and implications. Int J Rad Appl Instrum B 1989;16:121.
23. Seccamani E, Tattanelli M, Mariani M, et al. A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Int J Rad Appl Instrum B 1989;16:167.
24. Mueller BM, Reisfeld RA, Edgington TS, et al. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA 1990;87:5702.
25. Slavin-Chiorini DC, Kashmiri SV, Schlom J, et al. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 1995;55:5957S.
26. Slavin-Chiorini DC, Kashmiri SV, Lee HS, et al. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 1997;12:305.
27. Cook CH, Hinkle GH, Thurston MO, et al. Pharmacokinetics of Iodine-125 CC49 monoclonal antibody in patients with colon cancer. Cancer Biother Radiopharm 1996;11:415.
28. Khazaeli MB. Quantitation of mouse monoclonal antibody and human antimouse antibody design for radioimmunotherapy. Hybridoma 1989;8:231.
29. Forero A, Meredith RF, Khazaeli MB, et al. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 2003;18:751.
30. Everitt DE, Davis CB, Thompson K, et al. The pharmacokinectics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 1996;174:463.
31. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-hodgkin's lymphoma. J Clin Oncol 2003;16:3051.
32. Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance, and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998;17:110.
33. Agnese D, Abdessalam SF, Burak WE Jr, et al. Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma. Ann Surg Oncol 2004;11:197.